North America whole exome sequencing (WES) Market is projected to register a substantial CAGR of 22.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
Whole Exome Sequencing (WES) Market, By Component (Second generation sequencing and Third-Generation sequencing), Product and Service (systems, kits and services), Application (Drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others ), End User (pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others), Distribution Channel (direct trade, retail sales and others), Industry Trends and Forecast to 2029.
North America Whole Exome Sequencing (WES) market is categorized into four notable segment which is Component, Product and Service, Application, End User and Distribution Channel.
On the basis of component, the global whole exome sequencing (WES) market is segmented into second generation sequencing and third-generation sequencing.
On the basis of Product and Service, the global whole exome sequencing (WES) market is segmented into systems, kits and services.
On the basis of Application, the global whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.
On the basis of End user, the global whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.
On the basis of Distribution Channel, the global whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.
Some of the major factors contributing to the growth of the North America whole exome sequencing (WES) market are:
Increase in the adoption of whole exome sequencing (WES)
Growing usage of targeted sequencing methods
Market Players:
The key market players for North America whole exome sequencing (WES) market are listed below:
CD Genomics
Twist Bioscience
PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.)
GeneDx, LLC
Psomagen
TABLE OF CONTENTS
1 INTRODUCTION 33
- 1.1 OBJECTIVES OF THE STUDY 33
- 1.2 MARKET DEFINITION 33
- 1.3 OVERVIEW OF NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET 33
- 1.4 CURRENCY AND PRICING 35
- 1.5 LIMITATIONS 35
- 1.6 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
- 2.1 MARKETS COVERED 39
- 2.2 GEOGRAPHICAL SCOPE 40
- 2.3 YEARS CONSIDERED FOR THE STUDY 41
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 42
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
- 2.6 MULTIVARIATE MODELLING 46
- 2.7 MARKET APPLICATION COVERAGE GRID 47
- 2.8 PRODUCT TYPE LIFELINE CURVE 48
- 2.9 DBMR MARKET POSITION GRID 49
- 2.10 VENDOR SHARE ANALYSIS 51
- 2.11 SECONDARY SOURCES 52
- 2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHT 57
- 4.1 PORTER'S FIVE FORCES 58
- 4.2 PESTEL ANALYSIS 59
- 4.3 INDUSTRIAL INSIGHTS: 60
- 4.4 CONCLUSION 61
5 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: REGULATIONS 62
6 MARKET OVERVIEW 64
- 6.1 DRIVERS 66
- 6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS 66
- 6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 66
- 6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING 66
- 6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION 67
- 6.2 RESTRAINTS 68
- 6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS 68
- 6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 68
- 6.3 OPPORTUNITIES 69
- 6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 69
- 6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS 69
- 6.4 CHALLENGES 70
- 6.4.1 LACK OF SKILLED PROFESSIONALS 70
- 6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING 70
7 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT 71
- 7.1 OVERVIEW 72
- 7.2 SECOND-GENERATION SEQUENCING 75
- 7.2.1 SEQUENCING BY SYNTHESIS (SBS) 76
- 7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL) 76
- 7.3 THIRD-GENERATION SEQUENCING 77
8 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE 78
- 8.1 OVERVIEW 79
- 8.2 SYSTEMS 82
- 8.2.1 HISEQ SERIES 83
- 8.2.1.1 HISEQ 2500 83
- 8.2.1.2 HISEQ 1500 83
- 8.2.2 MISEQ SERIES 83
- 8.2.3 ION TORRENT PLATFORMS 84
- 8.2.3.1 ION PROTON 84
- 8.2.3.2 ION PGM 84
- 8.2.4 OTHERS 84
- 8.3 KITS 84
- 8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS 85
- 8.3.2 LIBRARY PREPARATION KITS 85
- 8.3.3 TARGET ENRICHMENT KITS 86
- 8.3.4 OTHERS 86
- 8.4 SERVICES 86
- 8.4.1 SEQUENCING SERVICES 87
- 8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES 87
- 8.4.3 OTHERS 87
9 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION 88
- 9.1 OVERVIEW 89
- 9.2 DRUG DISCOVERY AND DEVELOPMENT 92
- 9.3 AGRICULTURE & ANIMAL RESEARCH 93
- 9.4 DIAGNOSTICS 93
- 9.5 PERSONALIZED MEDICINE 94
- 9.6 OTHERS 95
10 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY END USER 96
- 10.1 OVERVIEW 97
- 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 100
- 10.3 ACADEMIC & RESEARCH INSTITUTES 101
- 10.4 HOSPITALS AND CLINICS 101
- 10.5 CLINICAL LABORATORIES 102
- 10.6 OTHERS 103
11 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL 104
- 11.1 OVERVIEW 105
- 11.2 DIRECT TRADE 108
- 11.3 RETAIL SALES 108
- 11.4 OTHERS 110
12 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY REGION 111
- 12.1 NORTH AMERICA 112
- 12.1.1 U.S. 120
- 12.1.2 CANADA 123
- 12.1.3 MEXICO 126
13 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE 129
- 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 129
14 COMPANY PROFILE 130
- 14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.) 130
- 14.1.1 COMPANY SNAPSHOT 130
- 14.1.2 REVENUE ANALYSIS 130
- 14.1.3 COM PANY SHARE ANALYSIS 131
- 14.1.4 PRODUCT PORTFOLIO 131
- 14.1.5 RECENT DEVELOPMENTS 131
- 14.2 MERCK KGAA 133
- 14.2.1 COMPANY SNAPSHOT 133
- 14.2.2 REVENUE ANALYSIS 133
- 14.2.3 COM PANY SHARE ANALYSIS 134
- 14.2.4 PRODUCT PORTFOLIO 134
- 14.2.5 RECENT DEVELOPMENTS 134
- 14.3 EXODX (A PART OF BIO-TECHNE) 135
- 14.3.1 COMPANY SNAPSHOT 135
- 14.3.2 REVENUE ANALYSIS 135
- 14.3.3 COM PANY SHARE ANALYSIS 136
- 14.3.4 PRODUCT PORTFOLIO 136
- 14.3.5 RECENT DEVELOPMENTS 136
- 14.4 THERMO FISHER SCIENTIFIC INC. 137
- 14.4.1 COMPANY SNAPSHOT 137
- 14.4.2 REVENUE ANALYSIS 137
- 14.4.3 COM PANY SHARE ANALYSIS 138
- 14.4.4 PRODUCT PORTFOLIO 138
- 14.4.5 RECENT DEVELOPMENTS 138
- 14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 139
- 14.5.1 COMPANY SNAPSHOT 139
- 14.5.2 REVENUE ANALYSIS 139
- 14.5.3 COM PANY SHARE ANALYSIS 140
- 14.5.4 PRODUCT PORTFOLIO 140
- 14.5.5 RECENT DEVELOPMENTS 140
- 14.6 AZENTA US, INC. 142
- 14.6.1 COMPANY SNAPSHOT 142
- 14.6.2 PRODUCT PORTFOLIO 142
- 14.6.3 RECENT DEVELOPMENTS 142
- 14.7 BECKMAN COULTER, INC 144
- 14.7.1 COMPANY SNAPSHOT 144
- 14.7.2 REVENUE ANALYSIS 144
- 14.7.3 PRODUCT PORTFOLIO 145
- 14.7.4 RECENT DEVELOPMENTS 145
- 14.8 BIONEER CORPORATION 146
- 14.8.1 COMPANY SNAPSHOT 146
- 14.8.2 REVENUE ANALYSIS 146
- 14.8.3 PRODUCT PORTFOLIO 147
- 14.8.4 RECENT DEVELOPMENTS 147
- 14.9 CD GENOMICS 148
- 14.9.1 COMPANY SNAPSHOT 148
- 14.9.2 PRODUCT PORTFOLIO 148
- 14.9.3 RECENT DEVELOPMENTS 148
- 14.10 CEGAT GMBH 149
- 14.10.1 COMPANY SNAPSHOT 149
- 14.10.2 PRODUCT PORTFOLIO 149
- 14.10.3 RECENT DEVELOPMENTS 149
- 14.11 EUROFINS SCIENTIFIC 150
- 14.11.1 COMPANY SNAPSHOT 150
- 14.11.2 REVENUE ANALYSIS 150
- 14.11.3 PRODUCT PORTFOLIO 151
- 14.11.4 RECENT DEVELOPMENTS 151
- 14.12 GENEDX, LLC 152
- 14.12.1 COMPANY SNAPSHOT 152
- 14.12.2 PRODUCT PORTFOLIO 152
- 14.12.3 RECENT DEVELOPMENTS 152
- 14.13 GENEFIRST LIMITED. 154
- 14.13.1 COMPANY SNAPSHOT 154
- 14.13.2 PRODUCT PORTFOLIO 154
- 14.13.3 RECENT DEVELOPMENTS 154
- 14.14 ILLUMINA, INC 156
- 14.14.1 COMPANY SNAPSHOT 156
- 14.14.2 REVENUE ANALYSIS 156
- 14.14.3 PRODUCT PORTFOLIO 157
- 14.14.4 RECENT DEVELOPMENTS 157
- 14.15 INTEGRATED DNA TECHNOLOGIES, INC. 159
- 14.15.1 COMPANY SNAPSHOT 159
- 14.15.2 PRODUCT PORTFOLIO 159
- 14.15.3 RECENT DEVELOPMENTS 159
- 14.16 MERIDIAN BIOSCIENCE, INC. 161
- 14.16.1 COMPANY SNAPSHOT 161
- 14.16.2 REVENUE ANALYSIS 161
- 14.16.3 PRODUCT PORTFOLIO 162
- 14.16.4 RECENT DEVELOPMENTS 162
- 14.17 PSOMAGEN 163
- 14.17.1 COMPANY SNAPSHOT 163
- 14.17.2 REVENUE ANALYSIS 163
- 14.17.3 PRODUCT PORTFOLIO 163
- 14.17.4 RECENT DEVELOPMENTS 164
- 14.18 QIAGEN 165
- 14.18.1 COMPANY SNAPSHOT 165
- 14.18.2 REVENUE ANALYSIS 165
- 14.18.3 PRODUCT PORTFOLIO 166
- 14.18.4 RECENT DEVELOPMENTS 166
- 14.19 SOPHIA GENETICS 167
- 14.19.1 COMPANY SNAPSHOT 167
- 14.19.2 REVENUE ANALYSIS 167
- 14.19.3 PRODUCT PORTFOLIO 168
- 14.19.4 RECENT DEVELOPMENTS 168
- 14.20 TWIST BIOSCIENCE 169
- 14.20.1 COMPANY SNAPSHOT 169
- 14.20.2 REVENUE ANALYSIS 169
- 14.20.3 PRODUCT PORTFOLIO 170
- 14.20.4 RECENT DEVELOPMENTS 170
15 QUESTIONNAIRE 172
16 RELATED REPORTS 175